This is an amended R01 to test the efficacy of cognitive behavioral therapy for adherence and depression (CBT-AD) in individuals with HIV and clinical depression who are in care for HIV. Clinical depression is one of the most frequently occurring (if not the most frequently occurring) and distressing conditions comorbid with HIV. Clinical depression consistently interferes with adherence and can affect medical outcome in individuals with HIV. Studies by the PI and others have shown that cognitive-behavioral interventions can be successful in improving HIV medication adherence. However, major depressive disorder may attenuate the degree to which individuals with HIV can benefit from such interventions. Despite the overwhelming evidence that depression is one of the most consistent predictors of poor adherence, interventions that incorporate treatment of depression with adherence training are lacking. Overview. Building on our prior work, this is a three-arm, randomized controlled efficacy trial of cognitive-behavioral therapy for major depressive disorder and HIV medication adherence in patients with HIV and major depressive disorder. Conceptual Model: Symptoms of major depressive disorder (e.g. low motivation, poor concentration, persistent loss of interest, sad mood, and suicidal ideation) in the context HIV infection are highly distressing and can substantially interfere with self-care behaviors necessary for managing HIV. Additionally, for individuals with major depressive disorder, attempts to improve adherence that do not address comorbid depression may be futile. We hypothesize that adding CBT for depression to adherence training will improve both mood and medication adherence, thereby promoting healthier living with HIV. Overview of Research Plan. Patients who are HIV infected and have a diagnosis of major depressive disorder will be randomized. The three arms are: (1) "CBT-AD," cognitive behavioral therapy for depression and adherence which lasts 12 sessions (2) "TMC" a time matched comparison group that involves our previously tested intervention for adherence (Life-Steps) delivered in an initial session in conjunction with education and support provided by a therapist, 3) ETAU - Enhanced Treatment as Usual - the single-session adherence intervention. All randomized participants, regardless of arm, will have feedback sent to their provider regarding baseline study assessments and treatment as it would normally occur. Participants will be followed for one-year post-randomization. Outcomes include adherence, depression, and HIV viral load. Additionally, we will collect resource utilization and cost data to examine the cost-effectiveness of reduced depression, and potentially, better HIV outcomes.

Public Health Relevance

Major depressive disorder is a frequently occurring, costly, distressing, interfering, and sometimes devastating disorder in individuals with HIV, and has consistently been shown to be associated with poor adherence to HIV medications. Interventions that incorporate evidenced based approaches to the treatment of depression with promotion of health behaviors are lacking for patients with medical conditions in general and HIV in particular. Following successful formative work through our NIMH R21, we propose a full-scale randomized controlled efficacy trial of cognitive behavioral therapy for adherence and depression in HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH084757-05
Application #
8324000
Study Section
Special Emphasis Panel (ZRG1-AARR-F (15))
Program Officer
Stirratt, Michael J
Project Start
2008-09-30
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$758,334
Indirect Cost
$187,964
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
O'Cleirigh, Conall; Valentine, Sarah E; Pinkston, Megan et al. (2015) The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, ART adherence, engagement in HIV care, and concurrent substance use. AIDS Behav 19:178-85
Blashill, Aaron J; Bedoya, C Andres; Mayer, Kenneth H et al. (2015) Psychosocial Syndemics are Additively Associated with Worse ART Adherence in HIV-Infected Individuals. AIDS Behav 19:981-6
Rajasingham, Radha; Mimiaga, Matthew J; White, Jaclyn M et al. (2012) A systematic review of behavioral and treatment outcome studies among HIV-infected men who have sex with men who abuse crystal methamphetamine. AIDS Patient Care STDS 26:36-52
Blashill, Aaron J; Perry, Nicholas; Safren, Steven A (2011) Mental health: a focus on stress, coping, and mental illness as it relates to treatment retention, adherence, and other health outcomes. Curr HIV/AIDS Rep 8:215-22
Safren, Steven A; Blashill, Aaron J; O'Cleirigh, Conall M (2011) Promoting the sexual health of MSM in the context of comorbid mental health problems. AIDS Behav 15 Suppl 1:S30-4
Gonzalez, Jeffrey S; Batchelder, Abigail W; Psaros, Cristina et al. (2011) Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr 58:181-7
Reisner, Sari L; Mimiaga, Matthew J; Skeer, Margie et al. (2009) A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med 17:14-25